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rBackground. Prophylactic intraaortic balloon pump
(IABP) support showed better outcomes in critical pa-
tients undergoing coronary revascularization compared
with intraoperative or postoperative insertion. We con-
ducted a prospective, randomized study to determine
the optimal timing for preoperative IABP insertion in
high-risk patients undergoing off-pump coronary ar-
tery revascularization.
Methods. The study enrolled 230 consecutive high-risk
patients (having a logistic European System for Cardiac
Operative Risk Evaluation score of >10) undergoing
off-pump coronary artery revascularization. They were
randomized for preoperative IABP starting at 2 hours (2T,
n 115) or 12 hours (12T, n  115). Clinical, biochemical,
nd hemodynamic results, and the need for inotropic
rug support, were markers of outcome and compared
etween groups.
Results. Hospital mortality in group 12T was reduced
y 60%, but the difference between groups was not
gery, University of Naples Federico II, Via S. Domenico 62, 80127 Naples,
Italy; e-mail vitomannacio2@libero.it.
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 byats.ctsnetjournals.orgDownloaded from tatistically significant (hazard ratio, 0.4; 95% confidence
nterval, 0.1 to 1.5; p  0.1). Twelve hours of preoperative
ABP therapy reduced postoperative low output syn-
rome (hazard ratio, 0.4; 95% confidence interval, 0.1 to
.9; p  0.03) and biomarker leakage upper normal limit
hazard ratio, 0.3; 95% confidence interval, 0.1 to 0.7; p 
.001). Postoperative left ventricular function was similar
etween the groups. Group 2T patients required higher
notropic support for a longer average duration and
rolonged postoperative intensive care unit and hospital
ength of stay.
Conclusions. Twelve hours preoperative IABP therapy
mproved treatment efficacy. Postoperative morbidity
as reduced, but hospital mortality rate was not affected.
he IABP-related complication rate was low and not
elated to the length of treatment.
(Ann Thorac Surg 2012;93:804–9)
© 2012 by The Society of Thoracic SurgeonsThe rapid development of invasive cardiology tech-niques has led to a changing pattern in the charac-
teristics of patients referred for coronary artery bypass
grafting (CABG). A larger proportion of patients coming
for surgical intervention are older, have more extensive
disease, present unstable angina, and poor left ventricu-
lar function, or a combination of these disorders. A
number of experiences from randomized trials and co-
hort studies reported a proven advantage from the use of
prophylactic preoperative intraaortic balloon pump
(IABP) support in those high-risk patients [1–5].
However, several questions remain unanswered re-
garding the optimal timing for preoperative IABP inser-
tion, which probably affects surgical outcome, intensive
care unit (ICU) stay, and total hospital length of stay. The
present randomized study was designed to determine
the best timing for preoperative IABP treatment in he-
modynamically stable high-risk patients undergoing off-
pump CABG. A number of clinical, hemodynamic and
biochemical findings were evaluated comparing two ho-
mogeneous groups of patients: one group received IABP
Accepted for publication Nov 23, 2011.
Address correspondence to Dr Mannacio, Department of Cardiac Sur-insertion 2 hours before induction of anesthesia and the
other was supported by IABP for 12 hours before CABG.
Material and Methods
The protocol for this study was approved by the Ethics
Committee of our institution and by the hospital’s Insti-
tutional Review Board. Informed consent was obtained
from each patient before enrolment in the study. The
study was not supported by any external source of
funding.
Patient Population and Study Design
This prospective randomized study was designed accord-
ing to the Consolidated Standards of Reporting Trials
statement. Between February 2005 and April 2011, 230
consecutive high-risk patients undergoing off-pump
CABG and matching the study selection criteria were
enrolled from a total of 3,009 patients undergoing off-
pump CABG in the same period.
The definition of high-risk patients was based on the
logistic European Risk Score System in Cardiac Opera-
tions (EuroSCORE) [6] and the cutoff of 10 points or
higher was chosen on the basis of the available literature
[6, 7]. The logistic EuroSCORE was calculated using the
current online version (www.euroscore.org/calc.html).
0003-4975/$36.00
doi:10.1016/j.athoracsur.2011.11.060
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CLeft main stem stenosis exceeding 90%, left main stenosis
exceeding 70%, and right coronary stenosis exceeding
70%, chronic occlusion of the 3 main coronary arteries,
acute ongoing angina or myocardial ischemia with failed
percutaneous coronary intervention were assigned to the
model as a critical preoperative state.
Patients included in the study had generally severe
coronary stenosis, such as left main stenosis exceeding
50% and right coronary stenosis, critical left main steno-
sis exceeding 70%, graft-dependent circulation in redo
cases, chronic occlusion of the 3 main coronary trunks
(left anterior descending, right and circumflex coronary
arteries), stenosis exceeding 99% of the proximal left
anterior descending coronary artery (before the first
septal or diagonal branch), and proximal stenosis ex-
ceeding 99% of a dominant right coronary artery with
remote branches for the posterior wall of the left
ventricle. Preoperative cardiogenic shock, additional
cardiac surgical procedures, and contraindications for
an off-pump operation were absolute exclusion crite-
ria. The study cohort was closely homogeneous for age,
sex, clinical features, and severity of coronary artery
disease (Table 1).
The study randomized 115 patients to preoperative
IABP treatment during 2 hours before induction of anes-
thesia (group 2T) and 115 to preoperative IABP treatment
during 12 hours before the operation (group 12T). Ran-
domization was obtained on admission by means of a
computer-generated algorithm and was fully blinded,
without any account of clinical or demographic features.
Table 1. Main Demographic and Clinical Characteristicsa
Variableb
Group 12T
(n  115)
Age, years 65.5  10.4 (43–8
Female sex 28 (24.3)
LVEF  0.35 62 (53.9)
LVEF 0.37  0.06
Myocardial infarction
90 days 55 (47.8)
90 days 38 (33)
Chronic pulmonary disease 59 (51.3)
Extracardiac arterioplasty 21 (18.2)
Neurologic dysfunction 8 (6.9)
Previous cardiac operation 11 (9.5)
Creatinine  20 mol/L 18 (15.6)
Critical preoperative state 75 (65.2)
Unstable angina 71 (61.7)
EuroSCORE, logistic 15.8  4.4 (11–22
Left main stenosis  90% 22 (19.1)
Triple vessel disease 82 (71.3)
Failed recent PCI 4 (3.4)
Diabetes mellitus 37 (32.1)
a Clinical and demographic variables were defined as used in the EuroS
(range) and categoric values as number (%).EuroSCORE  European System for Cardiac Operative Risk Evaluation; LV
intervention; 2T  2 hours of preoperative intraaortic balloon pump suppo
 byats.ctsnetjournals.orgDownloaded from Postoperative mortality and morbidity, as well as re-
quired in hospital or ICU stay, were registered for each of
the group.
Hemodynamic variables (cardiac output and systemic
vascular resistance indexed for body surface area, pul-
monary capillary wedge pressure, left ventricular stroke
work index, and mixed systemic venous oxymetry) were
recorded in all patients through a Swan-Ganz Combo
pulmonary artery catheter inserted just before IAPB
introduction and elaborated with a Vigilance CEDV
monitor (Edwards Lifesciences, Irvine, CA). Hemody-
namic variables were evaluated at any time during the
IABP time counterpulsation but were registered before
and after introduction of IABP, after anesthetic induction,
just before the sternal closure, and every 2 hours after the
operation until the IABP was removed.
Troponin I was evaluated before the operation and at 8,
12, 24, and 48 hours after, and then on every postopera-
tive day until hospital discharge. Troponin I was assayed
by means of a LIAISON kit (DiaSorin SpA, Saluggia,
Italy). Upper normal limits were 0.08 ng/mL, defined as
the 99th percentile of the value for the referenced con-
trolled group with a total imprecision of less than 10%,
according to Joint European Society of Cardiology/
American College of Cardiology guidelines [8].
The amount of inotropic pharmacologic support re-
quired to maintain a cardiac index (CI) greater than 2 L ·
min–1 · m–2 was monitored and used as a outcome
marker.
Group 2T
(n  115) p Value
63.2  11.7 (40–79) 0.1
32 (27.8) 0.6
59 (51.3) 0.7
0.38  0.07 0.2
58 (50.4) 0.7
41 (32) 0.7
54 (46.9) 0.5
28 (24.3) 0.3
3 (2.6) 0.2
14 (12.1) 0.6
13 (11.3) 0.4
71 (61.7) 0.6
74 (64.3) 0.7
16.1  4.5 (11–23) 0.6
20 (17.3) 0.8
85 (73.9) 0.7
2 (1.7) 0.6
48 (41.7) 0.1
. b Continuous values are expressed as mean  standard deviation1)
)
COREEF  left ventricular ejection fraction; PCI  percutaneous coronary
rt; 12T  12 hours of preoperative intraaortic balloon pump support.
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CSurgical Procedure
All patients underwent off-pump CABG through a me-
dian sternotomy. Extensive arterial grafting and com-
plete myocardial revascularization were preferred when-
ever possible. The left internal mammary artery was used
in all patients, and the right internal mammary artery
was the second-choice conduit when indicated. The ra-
dial artery was used as a Y-composite graft from the left
or the right internal mammary artery to the diagonal
artery or obtuse marginal coronary artery. The manda-
tory indication for radial artery use was critical stenosis
(85% to 90%) and good size and quality of the target
vessel. Saphenous veins were usually preferred for right
coronary artery revascularization as an aortocoronary
graft.
Suction devices to stabilize the target coronary artery
and intracoronary shunts were routinely used. Graft flow
was measured by means of a transit-time flowmeter in all
cases at the end of the procedure. A standardized proto-
col was followed in the ICU.
IABP Support
The intraaortic balloon (Datascope Sensation 7F, 40 mL;
Datascope Corp, Fairfield, NJ) was inserted percutane-
ously with sheathless technique and was connected to a
Datascope CS300 console (Datascope Corp). Insertion
through the best femoral artery was possible in all cases,
and the correct placement was assessed by chest roent-
genography. In 8 patients with severe peripheral vascular
disease, the intraaortic balloon was inserted under fluo-
roscopic control.
Intraaortic balloon pump assistance was set at a 1:1
ratio in all patients. Heparin was systematically used for
anticoagulation. After the operation, the IABP support
was terminated once hemodynamic stability was re-
stored: CI greater than 2.0 L · min–1 · m–2 with only
inimal inotropic support, and normal or nearly normal
ystemic vascular resistance. All IABP-related complica-
ions were recorded.
Definitions of Perioperative Data
Hospital mortality was defined as death occurring during
hospitalization. Conversion to cardiopulmonary bypass
was recorded as an unfavorable event. Postoperative
acute myocardial infarction was diagnosed when the
three different criteria indicated by the Joint European
Society of Cardiology/American College of Cardiology
guidelines were fulfilled [8].
Postoperative myocardial damage was defined as
troponin I leakage exceeding the normal upper limit on
two subsequent samples or maximal value exceeding
three times the normal upper limits on one occasion
without both electrocardiographic and echocardio-
graphic modifications [9].
Postoperative renal failure was defined as an in-
rease in serum creatinine value of greater than 2.5
g/dL. Low-output syndrome (LOS) was diagnosed
hen CI decreased to less than 2.0 L · min –1 · m–2,pulmonary capillary wedge pressure exceeded 15 mm
 byats.ctsnetjournals.orgDownloaded from Hg, left ventricular stroke work index (LVSWI) de-
creased to less than 22 g · m–1 · m–2, and results of
ixed systemic venous oxymetry were less than 60%
or at least 30 minutes after correction of all electrolyte
r blood gas abnormalities and after preload
ptimization.
High dose inotropic support was defined when greater
han 7 g · kg–1 · min–1 of dopamine or dobutamine was
iven or any dose of adrenaline was added.
Statistical Analysis
The primary outcome for sample size calculation was
hospital death after 12 hours of preoperative IABP sup-
port. On the assumption that a mean mortality rate of 6%
in high-risk patients undergoing IABP support during
the 1 to 2 hours before induction of anesthesia [10, 11], to
detect an absolute reduction of hospital mortality of 20%
after 12 hours of preoperative IABP support, at a 2-sided
 level of 0.05 and 80% power, 226 patients for both
sample were required. Therefore, 115 patients were en-
rolled in each group of study. Continuous variables are
expressed as means  standard deviation and categoric
data as percentages.
Comparisons of continuous variables between groups
were performed with the Student t test for normally
distributed values. The Mann-Whitney U test was used
for variables not normally distributed (biomarker and
hemodynamic values). Categoric variables were analyzed
with the 2 or Fisher exact tests, when appropriate. The
association between timing of IABP insertion and in-
hospital mortality and morbidity was modelled using
logistic regression and performed by calculating the
hazard ratio (HR) with 95% confidential intervals (CI).
Multiway analysis of variance with correction for serial
measurements was performed for hemodynamic data
and inotropic support evaluations. All variables with a
value of p  0.05 were considered significant. Statistical
nalysis was performed by SPSS 16.1 software (SPSS Inc,
hicago, IL).
Results
Operative Data
A total of 687 conduits were implanted. A mean of 2.99
(range, 1 to 5) grafts were implanted per patient: 3.0  1.2
n group 2T and 2.9  1.5 in group 12T (p  0.2). The
overall index of completeness (number of grafts per-
formed/number of grafts intended) was 0.92. Mean pro-
cedural time necessary to construct all anastomoses was
similar in both groups (p  0.8). The left anterior de-
scending artery was grafted in 227 patients (98.6%), the
circumflex artery in 206 (89.5%), and the right coronary
artery in 151 (65.6%). During the procedure, 34 patients
(21 in group 2T and 13 in group 12T) were converted to
cardiopulmonary bypass due to severe rhythm distur-
bances or hemodynamic instability, or both (p  0.1). In
those cases, revascularization was performed on the
beating heart under cardiac assistance.
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CHospital Mortality and Morbidity
Hospital mortality was 7.8% (10 patients) in group 2T and
4.3% (5 patients) in group 12T. Despite the apparent 60%
reduction of hospital mortality deriving from preopera-
tive 12-hour IABP support, this difference did not achieve
statistical significance in our population of patients (HR,
0.4; 95% CI, 0.1 to 1.5; p  0.1). The main causes of death
were low cardiac output due to left ventricular failure in
both groups. One patient in group 2T died of uncontrol-
lable arrhythmias and 1 patient in group 12T died of
multiorgan failure after pneumonia. Perioperative myo-
cardial infarction occurred in 10 patients (8.6%) from
group 2T and in 5 (4.3%) from group 12T (p  0.2).
Mean preoperative values of troponin I were similar in
the two groups. Postoperative biomarker leakage at the
upper normal limit occurred in 92 patients (80%) from
group 2T vs 69 (60%) from group 12T (Fig 1). Twelve
hours of IABP treatment before CABG was associated
with a 25% reduction in risk of troponin I leakage at the
upper normal limit (HR, 0.3; 95% CI, 0.1 to 0.7; p  0.001),
although the greater risk factors the patients had, the
higher the biomarker leakage.
No hemodynamic difference was observed between
groups preoperatively. An initial significant reduction of
CI and LVSWI was observed in group 2T compared with
group 12T after the induction of anesthesia and in the
early phase of the operation. A tendency to better cardiac
indices was not registered in either group during the
operation. The magnitude of postoperative CI and
LVSWI maximal decline was not significant between
groups. However, high doses of inotropic drugs were
necessary in 25 patients (21.7%) of group 12T vs 42
patients (36.5%) of group 2T (p  0.02) for a longer
average duration (Table 2). Twelve hours of preoperative
treatment with IABP was associated with a 30% reduction
of patients who required high doses of inotropic support
(HR, 0.4; 95% CI, 0.2 to 0.8; p  0.02). CI and LVSWI
declined to the lowest 4 hours postoperatively in each
group. CI recovered to the preoperative level 34  13
hours after CABG in group 2T and at 30  11 hours in
Fig 1. Cardiac marker elevations in patients who received 2 hours
(group 2T) and 12 hours (group 12T) of preoperative intraaortic bal-
loon pump assistance. Incidence of postoperative increase of tro-
ponin I was 1 to 3 times (white section) and 3 times (black sec-
tion) above the upper normal limit.
h
I
 byats.ctsnetjournals.orgDownloaded from group 12T (p  0.01), whereas LVSWI recovered to the
preoperative level 41  18 hours after CABG in group 2T
and at 36  14 hours in group 12T (p  0.01).
Postoperative LOS occurred in 22 patients (19.1%) from
group 2T vs 10 (8.8%) from group 12T. Twelve hours
preoperative treatment with IABP was associated with a
54% reduction in risk of LOS (HR, 0.4; 95% CI, 0.1 to 0.9;
p  0.03). Most patients with postoperative LOS experi-
enced renal failure as well as gastrointestinal and respi-
ratory complications and required prolonged IABP assis-
tance and ventilation support.
No major IABP-related complications were registered
postoperatively, except for 3 group 12T patients with
temporary limb ischemia that resolved completely after
prompt IABP withdrawal. Three minor postoperative
complications, consisting of bleeding at the balloon entry
site that resolved with manual compression, were equally
distributed between the groups. Mean postoperative
IABP time was longer in group 2T (68  26 vs 52  21
hours; p  0.005), as was mechanical ventilation time
(12  5 vs 10  4 hours; p  0.001), postoperative ICU
4.2  1.7 vs 3.7  1.1 days; p  0.01), and hospital length
f stay (13.1  3.8 vs 11.4  2.5 days; p  0.001). Nonfatal
ostoperative complications were few and evenly distrib-
ted between the groups (Table 3). The effect of the
Table 2. Doses of Inotropic Drugs
Drug
Group 12T
(n  115)
No. (%)
Group 2T
(n  115)
No. (%)
p
Values
opa/DBT 7 g · kg–1 ·
min–1
90 (78.3) 73 (63.5) 0.02
opa/DBT 7 g · kg–1 ·
min–1
15 (13.1) 22 (19.2) 0.1
opa/DBT  adrenaline 10 (8.6) 20 (17.3) 0.03
DBT  Dobutamine; 2T  2 hours of preoperative intraaortic balloon
pump support; 12T  12 hours of preoperative intraaortic balloon
ump support.
Table 3. Operative Resultsa
Variable
Group 12T
(n  115)
Group 2T
(n  115)
p
Value
ompleteness index 0.90 0.92 1
entilation support, hours 10  4 12  5 0.001
ostop IABP support, hours 52 21 68  26 0.005
ength of stay, days
Intensive care unit 3.7  1.1 4.2 1.7 0.001
Hospital 11.4  2.5 13.1 3.8 0.001
eoperation for bleeding 2 (1.7) 3 (2.6) 0.5
enal failure 3 (2.6) 5 (4.3) 0.3
ABP-related complication 4 (3.4) 2 (1.7) 0.3
neumonia 2 (1.7) 8 (6.9) 0.05
a Continuous values are expressed as mean  standard deviation and
ategoric values as number (%).
ABP  intraaortic balloon pump; Postop  postoperative; 2T  2
ours of preoperative IABP support; 12T  12 hours of preoperative
ABP support.
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Cpreoperative IABP treatment length on main morbidity
and mortality is reported in Table 4.
Comment
Several clinical studies have reported worse outcome and
high rates of complications in patients who required
placement of emergency IABP support during intraoper-
ative or postoperative critical hemodynamic decompen-
sation [1, 4, 12]. Preoperative prophylactic IABP support
has recently been suggested to have proven efficacy in
significantly lowering hospital mortality and morbidity in
high-risk coronary patients undergoing CABG [1–3, 10–13].
The Benchmark Registry and The Society of Thoracic
Surgeons National Database report that preoperative
IABP use is associated with reduced mortality of 8.8%
and 9.5%, respectively, compared with 28.2% and 23.5%,
respectively, with intraoperative IABP use [14]. These
results have also been confirmed by a significant reduc-
tion in death in high-risk patients than that expected
according to the logistic EuroSCORE.
The positive effect of preoperative insertion of IABP in
high-risk patients is thought to be due to an improved
myocardial oxygen supply/demand ratio and reduced
ventricular wall stress before the operation in addition to
diastolic augmentation and decreased afterload resulting
in the redistribution of coronary blood flow toward the
ischemic areas of the myocardium, and in the recovered
energy depletion of myocardial cells [15]. As a conse-
quence, preoperative prophylactic IABP assistance pro-
vides better hemodynamic stability in the crucial times
for higher oxygen demand when the anesthesia is in-
duced and the conduits are harvested, as well as when
the heart is displaced in off-pump procedures [5, 16–18].
The optimal timing for preoperative insertion of IABP
in high-risk patients undergoing CABG remains contro-
versial, although the subject has been treated frequently
in the past decade. The unanswered question about
whether the surgical outcome is time-related to the
length of prophylactic preoperative IABP treatment is
still challenging. Preoperative balloon counterpulsation
should be neither too long, in an effort to minimize the
complications rate that seems time-dependent during
IABP use, nor too short, leading to impaired metabolic
Table 4. Impact of Preoperative Intraaortic Balloon Pumping
Variable
Group 12T
(n  115)
No. (%)
Hospital death 5 (4.3)
Myocardial damage 69 (60)
Low output syndrome 10 (8.8)
High inotrope doses 25 (21.7)
Myocardial infarction 5 (4.3)
Conversion to CPB 13 (11.3)
CI  confidence interval; CPB  cardiopulmonary bypass; HR
support; 12T  12 hours of preoperative intraaortic balloon pump suand hemodynamic recovery.
 byats.ctsnetjournals.orgDownloaded from The time-related results for preoperative insertion of
the IABP on a randomized basis were investigated by
Christenson and colleagues [11] in a cohort of high-risk
patients who underwent CABG. They found no differ-
ence in outcome whether the IABP was inserted 2, 12, or
24 hours preoperatively, whereas results of intraopera-
tive or postoperative IABP insertion were disappointing
owing to an associated high mortality and complications
rate [11]. Their study is the only randomized trial in the
literature; unfortunately, it was underpowered to detect
statistically significant differences among the groups.
Hence, the results remain insufficiently robust enough to
validate the prophylactic insertion of IABP only 2 hours
before CABG in truly elective high-risk patients.
Our study was designed to define the optimal time for
IABP insertion by comparative evaluation of two ran-
domized groups of patients. Both study arms were ho-
mogeneous regarding the possible misleading factors for
such a study. Demographic, clinical, and operative char-
acteristics were similar between the groups as well as the
index of completeness, as complete revascularization was
the principal advantage of the cardiac operations and
was essential in such cohort of high-risk patients.
Our results evidenced that preoperative IABP insertion
12 hours before operation did not carry a statistically
significant survival advantage compared with 2 hours of
preoperative treatment. However, longer prophylactic
support with IABP resulted in a significant reduction of
postoperative LOS rate, of assisted ventilation time, as
well as hospital and ICU length of stay.
Preoperative IABP treatment resulted in similar post-
operative cardiac function in both groups in maximal
decline of CI and LWSWI. However, patients who expe-
rienced balloon insertion 2 hours before CABG required
higher doses of inotropic drugs for a longer time and
showed significantly higher biomarker leakage. It is
clear, therefore, that 12 hours of preoperative IABP
support provides good myocardial preservation, better
hemodynamic stability and coronary perfusion, mini-
mizes inotropic support, and reduces the incidence of
LOS.
Intraaortic balloon pump insertion can occasionally be
cumbersome or risky because of severe and diffuse
atherosclerosis of the descending aorta and peripheral
th on Postoperative Main Morbidity and Mortality
roup 2T
n  115)
No. (%) HR (95% CI) p Value
0 (7.8) 0.4 (0.1–1.5) 0.1
0 (80) 0.3 (0.1–0.7) 0.001
2 (19.1) 0.4 (0.1–0.9) 0.03
2 (36.5) 0.4 (0.2–0.8) 0.02
0 (8.6) 0.4 (0.1–1.5) 0.2
1 (18.2) 0.5 (0.2–1.2) 0.2
zard ratio; 2T  2 hours of preoperative intraaortic balloon pump
.Leng
G
(
1
9
2
4
1
2arteries, or even contraindicated because of abdominal
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Caortic aneurysms. The major disadvantages related to
IABP use thus far were complications associated with its
placement, mainly bleeding, vascular injury, and limb
ischemia [19].
Despite the presence of peripheral vascular disease in
ore than 25% of the patients and regardless the period
f preoperative IABP treatment, the overall incidence of
ABP-related complication rate was low in this study
2.6%) compared with the Benchmark Registry (7.0%)
20]. Complications were all reversible, at most with
iscontinuation and removal of the balloon. The low
ncidence of IABP-related complications reported in this
tudy was probably due to planned preoperative inser-
ion as well as to smaller-caliber 7F catheters, sheathless
lacement techniques, and careful surveillance of pa-
ients focused on IABP-related complications. Further-
ore, advances in IABP design, such as fiberoptic tech-
ology, reduction of need for repeated zeroing, and
utomatic trigger modes, have made handling of balloon
umps simpler, more accurate, and user-friendly.
In conclusion, 12-hour preoperative IABP treatment
mproved cardiac performance, reduced inotropic re-
uirements, and shortened ICU and hospital length of
tay significantly. A short preoperative IABP treatment
eems to be a less attractive alternative because it was
ssociated with higher morbidity and ICU and hospital
tay. Preoperative insertion of IABP was safe and not
ssociated with postoperative significant complications
egardless, the counterpulsation time.
The authors are grateful to Dr GiovanBattista Mannacio from
the Imperial College, London, for assistance with statistical
analysis.
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